Journal of eISSN: 2574-9943 JDC

Dermatology & Cosmetology
Mini Review
Volume 2 Issue 1

Do human papilloma viruses play a role in the genesis of cutaneous malignancies?
Mohamed JEMF Mabruk
Department of Allied Health Sciences, Sultan Qaboos University, Oman
Received: October 12, 2017 | Published: February 02, 2018

Correspondence: Mohamed JEMF Mabruk, College of Medicine and Department of Allied Health Sciences Allied Health Sciences, Sultan Qaboos University, Al Khoudh, Muscat 123, Oman, Tel +96824143464, Fax +96824413419, Email

Citation: Mabruk MJEMF. Do human papilloma viruses play a role in the genesis of cutaneous malignancies? J Dermat Cosmetol. 2018;2(1):30‒32. DOI: 10.15406/jdc.2018.02.00033

Abstract

The role of human papillomavirus (HPV) infection in the genesis of cutaneous malignancies with special reference to cutaneous squamous cell carcinoma (SCC) remains a mystery. Recent evidence suggests that certain circumstances, such as allograft transplantation or genetic predisposition may allow infection with HPV to result in cutaneous malignancy.

Keywords: human papillomavirus, cutaneous malignancies, bak, viral genome, skin carcinogenesis

Abbrevations

HPV, human papillomavirus; SCC, squamous cell carcinoma; EV, epidermodysplasia verruciformis; UV, ultraviolet; MAML-1, mastermind-like protein-1

Introduction

The human papillomavirus is a double-stranded DNA virus that infects the epithelial cells of skin and mucosa.1 The family of papillomaviridae consists of around 200 different human papillomavirus types.2 The various types and subtypes of HPV are distinguished on the basis of their nucleic acid sequence.3

HPVs have been divided into 5 genera: Alpha-papillomavirus, Beta-papillomavirus, Gamma-papillomavirus, Mu-papillomavirus and Nu-papillomavirus.4,5 Members of the genus alpha HPV types are known to induce benign skin warts, genital warts and cervical cancer.6–8 Genus beta HPV were identified in flat warts and in cutaneous squamous cell carcinomas in epidermodysplasia verruciformis (EV) patients.9,10 EV effected individuals are often infected with HPV types and many develop squamous cell carcinomas (SCCs) at body sites exposed to sunlight.11 EV specific HPV types include HPV5 and HPV8 and to a lesser extent HPV14, and HPV20.12,13 It has been suggested that, the increase of risk of cutaneous malignancies in sun exposed area in EV patients may indicate correlation between DNA damage induced by Ultraviolet irradiation (UV) and the infection with beta HPV virus.14–16

The prevalence of beta-HPV DNA was found to be higher in premalignant lesions and SCC in immunocompromised individuals in comparison to immune competent patients.17,18 The higher rate of cutaneous malignancies among immunocompromised patients suggests that HPV may play a role in the genesis of this type of malignancies.

Previous studies showed that HPV viral load is decreased during skin carcinogenesis and significantly higher in actinic keratosis than in SCC.14,19 This led to the suggestion that the virus may play a role in the early stages of SCC development and that the role of HPV would be initiation of malignancies rather than maintenance.14 This may indicate that the beta-HPV is playing a role in the initiation of malignancy by destabilizing the host genome by allowing the persistence of mutations that can drive tumorigenesis independently of the viral genome.20

Discussion

The HPV genome may explain how this mysterious virus may contribute to malignancy. It consists of approximately 8000 base-pairs of double stranded, circular DNA that encode 9-10 open reading frames.21,22 The HPV genes are designated as early (E) and late (L) genes.23 The early genes include E1, E2, E3, E4, E5, E6 and E7.21 The late genes include L1 and L2 genes.21 The L1 and L2 are major and minor capsid subunits respectively, and these are the structural proteins of the virion.21,22

The viral E1 and E2 proteins are responsible for perverting normal cellular processes in order to reproduce the viral genome.24 It has been shown that the early genes E6 and E7 encode the viral oncoproteins and they are the major transforming proteins of HPV.25,26

Other studies indicated that E5 of high risk types of HPV may play a role in the genesis of cervical cancer.27 The cellular target of E6 oncoprotein of alpha HPV in cervical cancer, is the tumor suppressor gene p53.26,28,29 The interaction of E6 oncoprotein with p53 results in its degradation and this may contribute to this type of malignancy.26

The E7 oncoprotein of alpha HPV in cervical cancer destabilize pRB through proteasomal degradation.30 Deactivation of pRB results in displacement and thereby activation of E2F and thus contributing to cellular transformation.31 In regard to the oncoproteins E6 and E7 of beta HPVs, previous studies conducted in tissue culture and in transgenic mice showed clearly that E6 and E7 display transforming activities and the transformation activities are enhanced following exposure to Ultraviolet irradiation.32,33 These finding may further confirm the potential role of this HPV type in the genesis of cutaneous carcinogenesis. It has been proposed that the genus beta HPV E6 proteins inhibit at least some p53 target genes, although perhaps not by the same mechanism or to the same degree as the high-risk genus alpha HPV E6 proteins.34

Furthermore, the E6 protein of cutaneous HPV types was shown to interfere with DNA damage repair35 and to inhibit apoptosis in keratinocytes in response to UV irradiation.36,37 The inhibition of apoptosis in keratinocytes was due to the capabilities of the E6 protein of HPV to degrade cell mediated apoptosis protein “Bak.38” The capabilities of E6 protein of beta HPV to interfere to some degrees with the tumor suppressor gene p53 and with the DNA damage repair mechanisms and to inhibit the induction of apoptosis may explain how this virus may contribute to cutaneous malignancies.

The E6 protein of beta HPV is also shown to target Mastermind-Like protein-1 (MAML1), which is known to act as transcriptional co-activator for NOTCH protein.39,40 NOTCH pathways play an important pro-differentiation role and have a tumor suppressing function in keratinocytes.41

On the other hand, the cutaneous beta HPV E7 oncoprotein is shown to bind pRB with lower efficiency than the high-risk HPV E7 proteins.42 However, this could be contributed to the type of beta HPV type involved, this suggestion was supported by previous work by Cornet I et al.,43 who compared the properties of E6 and E7 oncoproteins from six uncharacterized beta HPVs types (14,22,23,24,36,49) and found that only HPV49 E6 and E7 immortalized primary human keratinocytes and efficiently deregulated the p53 and pRb pathways.44

Conclusion

It appears that HPV is playing somehow a role in the initiation and genesis of cutaneous malignancies and more studies are needed in order to determine the carcinogenic properties of HPVs and their potential role in skin cancer development.

Acknowledgements

None.

Conflict of interest

The author declares no conflicts of interest.

References

  1. Stanley MA. Epithelial cell responses to infection with human papillomavirus. Clin Microbiol Rev. 2012;25(2):215–222.
  2. Burk RD, Harari A, Chen Z. Human papillomavirus genome variants. Virology. 2013;445(1-2):232–243.
  3. Chan SY, Delius H, Halpern AL, et al. Analysis of genomic sequences of 95 papillomavirus types: uniting typing, phylogeny, and taxonomy. J Virol. 1995;69(5):3074–3083.
  4. De Villiers EM, Fauquet C, Broker TR, et al. Classification of papillomaviruses. Virology. 2004;324(1):17–27.
  5. Chouhy D, Bolatti EM, Pérez GR, et al. Analysis of the genetic diversity and phylogenetic relationships of putative human papillomavirus types. J Gen Virol. 2013;94(Pt 11):2480–2488.
  6. Bosch FX, Lorincz A, Muñoz N. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55(4):244–265.
  7. Viens LJ, Henley SJ, Watson M, et al. Human papillomavirus-associated cancers-United States, 2008-2012. Morb Mortal. 2016;65(26):661–666.
  8. Bzhalava D, Guanb P, Franceschi S, et al. A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types. Virology. 2013;445(1-2):224–231.
  9. Orth G. Epidermodysplasia verruciformis: A model for understanding the oncogenicity of human papillomaviruses. Ciba Found Symp. 1986;120:157–174.
  10. Pfister H. Biology of epidermodysplasia verruciformis-associated HPV. Hautarzt. 2011;62(1):17–21.
  11. Pfister H. Human papillomaviruses and skin cancer. Semin Cancer Biol. 1992;3(5):263–271.
  12. Yutsudo M, Tanigaki T, Kanda R, et al. Involvement of human papillomavirus type 20 in epidermodysplasia verruciformis skin carcinogenesis. J Clin Microbiol. 1994;32(4):1076–1078.
  13. Weissenborn SJ, Höpfl R, Weber F, et al. High prevalence of a variety of epidermodysplasia verruciformis-associated human papillomaviruses in psoriatic skin of patients treated or not treated with PUVA. J Invest Dermatol. 1999;113(1):122–126.
  14. Howely PM, Pfister HJ. Beta Genus Papillomaviruses and skin cancer. Virology. 2015;480:290–296.
  15. Forslund O, Iftner T ,Andersson K, et al. Cutaneous human papillomaviruses found in sun-exposed skin: beta-papillomavirus species 2 predominates in squamous cell carcinoma. J Infect Dis. 2007;196(6):876–883.
  16. Hufbauer M and Akgül B. Molecular mechanisms of human papillomavirus induced skin carcinogenesis. Viruses. 2017;9(7):pii: E187.
  17. Reusser NM, Downing C, Guidry J, et al. HPV Carcinomas in immunocompromised patients. J Clin Med. 2015;4(2):260–281.
  18. Aldabagh B, Angeles JG, Cardones AR, et al. Cutaneous squamous cell carcinoma and human papillomavirus: is there an association? Dermatol Surg. 2013;39(1 Pt 1):1–23.
  19. Wieland U, Kreuter A, Pfister H. Human papillomavirus and immunosuppression. Curr Probl Dermatol. 2014;45:154–165.
  20. Wallace NA, Robinson K, Galloway DA. Beta human papillomavirus E6 expression inhibits stabilization of p53 and increases tolerance of genomic instability. J Virol. 2014;88(11):6112–6127.
  21. Danos O, Katinka M, Yaniv M. Human papillomavirus 1a complete DNA sequence: a novel type of genome organization among papovaviridae. EMBO J. 1982;1(2):231–236.
  22. Graham SV. Human papillomavirus: gene expression, regulation and prospects for novel diagnostic methods and antiviral therapies. Future Microbiol. 2010;5(10):1493–1506.
  23. Zheng ZM and Baker CC. Papillomavirus genome structure, expression, and post-transcriptional regulation. Front Biosci. 2006;11:2286–2302.
  24. Hoffmann R, Hirt B, Bechtold V, et al. Different modes of human papillomavirus DNA replication during maintenance. J Virol. 2006;80(9):4431–4439.
  25. Yim EK, Park JS. The role of HPV E6 and E7 Oncoproteins in HPV-associated cervical carcinogenesis. Cancer Res Treat. 2005;37(6):319–324.
  26. Tomaić V. Functional Roles of E6 and E7 oncoproteins in HPV-induced malignancies at diverse anatomical sites. Cancers (Basel). 2016;8(10):95.
  27. Liao S, Deng D, Zhang W, et al. Human papillomavirus 16/18 E5 promotes cervical cancer cell proliferation, migration and invasion in vitro and accelerates tumor growth in vivo. Oncol Rep. 2013;29(1):95–102.
  28. Thomas M, Pim D, Banks L. The role of the E6-p53 interaction in the molecular pathogenesis of HPV. Oncogene. 1999;18(53):7690–7700.
  29. Brimer N, Vande Pol SB. Papillomavirus E6 PDZ interactions can be replaced by repression of p53 to promote episomal human papillomavirus genome maintenance. J Virol. 2014;88(5):3027–3030.
  30. McLaughlin-Drubin ME, Münger K. The human papillomavirus E7 oncoprotein. Virology. 2009;384(2):335–344.
  31. Jansma AL, Martinez-Yamout MA, Liao R, et al. The high-risk HPV16 E7 oncoprotein mediates interaction between the transcriptional coactivator CBP and the retinoblastoma protein pRb. J Mol Biol. 2014;426(24):4030–4048.
  32. Schaper ID, Marcuzzi GP, Weissenborn SJ, et al. Development of skin tumors in mice transgenic for early genes of human papillomavirus type 8. Cancer Res. 2005;65(4):1394–1400.
  33. Marcuzzi GP, Hufbauer M, Kasper HU, et al. Spontaneous tumour development in human papillomavirus type 8 E6 transgenic mice and rapid induction by UV-light exposure and wounding. J Gen Virol. 2009;90(Pt 12):2855–2864.
  34. White EA, Walther J, Javanbakht H, et al. Genus beta human papillomavirus E6 proteins vary in their effects on the transactivation of p53 target genes. J Virol. 2014;88(15):8201–8212.
  35. Giampieri S, Storey A. Repair of UV-induced thymine dimers is compromised in cells expressing the E6 protein from human papillomaviruses types 5 and 18. Br J Cancer. 2004;90(11):2203–2209.
  36. Jackson S, Storey A. E6 proteins from diverse cutaneous HPV types inhibit apoptosis in response to UV damage. Oncogene. 2000;19(4):592–598.
  37. Jackson S, Harwood C, Thomas M, Banks L, et al. Role of Bak in UV-induced apoptosis in skin cancer and abrogation by HPV E6 proteins. Genes Dev. 2000;14(23):3065–3073.
  38. Underbrink MP, Howie HL, Bedard KM, et al. E6 proteins from multiple human betapapillomavirus types degrade Bak and protect keratinocytes from apoptosis after UVB irradiation. J Virol. 2008;82(21):10408–10417.
  39. Brimer N, Lyons C, Wallberg AE, et al. Cutaneous papillomavirus E6 oncoproteins associate with MAML1 to repress transactivation and NOTCH signalling. Oncogene. 2012;31(43):4639–4646.
  40. Meyers JM, Spangle JM, Munger K. The human papillomavirus type 8 E6 protein interferes with NOTCH activation during keratinocyte differentiation. J Virol. 2013;87(8):4762–4767.
  41. Datto GP. Notch tumor suppressor function. Oncogene. 2008;27(38):5115–5123.
  42. Cornet I, Bouvard V, Campo MS, et al. Comparative analysis of transforming properties of E6 and E7 from different beta human papillomavirus types. J Virol. 2012;86(4):2366–2370.
  43. Gage JR, Meyers C, Wettstein FO. The E7 proteins of the nononcogenic human papillomavirus type 6b (HPV-6b) and of the oncogenic HPV-16 differ in retinoblastoma protein binding and other properties. J Virol. 1990;64(2):723–730.
©2018 Mabruk. This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and build upon your work non-commercially.
© 2014-2018 MedCrave Group, All rights reserved. No part of this content may be reproduced or transmitted in any form or by any means as per the standard guidelines of fair use.
Creative Commons License Open Access by MedCrave Group is licensed under a Creative Commons Attribution 4.0 International License.
Based on a work at https://medcraveonline.com
Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version | Opera |Privacy Policy